Nathalie Scholler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nathalie Scholler has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
Adrian Bot
9 shared publicationsAleksandra Wroblewska
7 shared publicationsAlessandro Lagana
7 shared publicationsAlessia Baccarini
7 shared publicationsBrian D. Brown
7 shared publicationsGvantsa Pantsulaia
7 shared publications
Latest Publications
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
Table 1 from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
Table 1 from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
The genetic reprogramming of T cells with chimeric antigen receptors (CAR) specifically targeting CD19 in B-cell malignancies or B-cell maturation antigen for plasma cell tumors has achieved remarkable success. CAR T-cell therapy represents a revolutionary strategy in personalized cancer care, leveraging the immune system's precision to target cancer cells with unprecedented efficacy. However, challenges persist, with resistance and relapse occurring in hematologic malignancies. Understanding the intricate mechanisms governing response and resistance is crucial, emphasizing factors such as pharmacokinetics, product attributes, and tumor biology. This review focuses on biomarkers associated with CAR T-cell therapy in mature B-cell non-Hodgkin lymphoma malignancies, underscoring the importance of preexisting tumor immune contexture. Previous findings highlight strong correlation between early peak levels of CAR-T cells after treatment initiation and treatment response. Maintaining an optimal CAR T-cell–to–tumor burden ratio is essential for sustained responses. Systemic and tumor immune contexture affects therapy outcomes, revealing preexisting immunity's role in CAR T-cell efficacy. The mechanistic impact of CAR-T cells was investigated using pre- and posttreatment biopsies, revealing specific markers associated with treatment response in refractory large B-cell lymphoma, across patients receiving CAR T-cell therapy in the second- and third-line settings, supporting precision medicine in developing next-generation cell therapies for hematologic malignancies. The evolution of the tumor microenvironment with therapy lines was also demonstrated, supporting earlier intervention with CAR T-cell therapy. Ongoing translational efforts, including single-cell omics analysis, aim to uncover additional factors that affect outcomes to develop more potent treatments.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
The genetic reprogramming of T cells with chimeric antigen receptors (CAR) specifically targeting CD19 in B-cell malignancies or B-cell maturation antigen for plasma cell tumors has achieved remarkable success. CAR T-cell therapy represents a revolutionary strategy in personalized cancer care, leveraging the immune system's precision to target cancer cells with unprecedented efficacy. However, challenges persist, with resistance and relapse occurring in hematologic malignancies. Understanding the intricate mechanisms governing response and resistance is crucial, emphasizing factors such as pharmacokinetics, product attributes, and tumor biology. This review focuses on biomarkers associated with CAR T-cell therapy in mature B-cell non-Hodgkin lymphoma malignancies, underscoring the importance of preexisting tumor immune contexture. Previous findings highlight strong correlation between early peak levels of CAR-T cells after treatment initiation and treatment response. Maintaining an optimal CAR T-cell–to–tumor burden ratio is essential for sustained responses. Systemic and tumor immune contexture affects therapy outcomes, revealing preexisting immunity's role in CAR T-cell efficacy. The mechanistic impact of CAR-T cells was investigated using pre- and posttreatment biopsies, revealing specific markers associated with treatment response in refractory large B-cell lymphoma, across patients receiving CAR T-cell therapy in the second- and third-line settings, supporting precision medicine in developing next-generation cell therapies for hematologic malignancies. The evolution of the tumor microenvironment with therapy lines was also demonstrated, supporting earlier intervention with CAR T-cell therapy. Ongoing translational efforts, including single-cell omics analysis, aim to uncover additional factors that affect outcomes to develop more potent treatments.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
Schematic representation of CAR T-cell structure and mechanism of action. Designed CAR receptors comprising a receptor domain, CD28 co-stimulatory domain, and CD3ζ activation domain bind to CD19 antigens on the surface of lymphoma cells. This binding event initiates T-cell activation, triggering the release of granzymes and cytokines. Preexisting immune cells, including T cells and myeloid cells, support CAR-T cells through the production granzymes, cytokines, and chemokines. This process induces the targeted death of B-cell lymphoma. CCL2, chemokine ligand 2; CCL5, chemokine ligand 5; CXCL9, C-X-C motif chemokine ligand 9; GNLY, granulysin; GZMA, granzyme A; GZMB, granzyme B; ScFv, single-chain variable fragment.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
Schematic representation of CAR T-cell structure and mechanism of action. Designed CAR receptors comprising a receptor domain, CD28 co-stimulatory domain, and CD3ζ activation domain bind to CD19 antigens on the surface of lymphoma cells. This binding event initiates T-cell activation, triggering the release of granzymes and cytokines. Preexisting immune cells, including T cells and myeloid cells, support CAR-T cells through the production granzymes, cytokines, and chemokines. This process induces the targeted death of B-cell lymphoma. CCL2, chemokine ligand 2; CCL5, chemokine ligand 5; CXCL9, C-X-C motif chemokine ligand 9; GNLY, granulysin; GZMA, granzyme A; GZMB, granzyme B; ScFv, single-chain variable fragment.
- Open Access
- 7 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (18) , 3834-3843
Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
The genetic reprogramming of T cells with chimeric antigen receptors (CAR) specifically targeting CD19 in B-cell malignancies or B-cell maturation antigen for plasma cell tumors has achieved remarkable success. CAR T-cell therapy represents a revolutionary strategy in personalized cancer care, leveraging the immune system's precision to target cancer cells with unprecedented efficacy. However, challenges persist, with resistance and relapse occurring in hematologic malignancies. Understanding the intricate mechanisms governing response and resistance is crucial, emphasizing factors such as pharmacokinetics, product attributes, and tumor biology. This review focuses on biomarkers associated with CAR T-cell therapy in mature B-cell non-Hodgkin lymphoma malignancies, underscoring the importance of preexisting tumor immune contexture. Previous findings highlight strong correlation between early peak levels of CAR-T cells after treatment initiation and treatment response. Maintaining an optimal CAR T-cell–to–tumor burden ratio is essential for sustained responses. Systemic and tumor immune contexture affects therapy outcomes, revealing preexisting immunity's role in CAR T-cell efficacy. The mechanistic impact of CAR-T cells was investigated using pre- and posttreatment biopsies, revealing specific markers associated with treatment response in refractory large B-cell lymphoma, across patients receiving CAR T-cell therapy in the second- and third-line settings, supporting precision medicine in developing next-generation cell therapies for hematologic malignancies. The evolution of the tumor microenvironment with therapy lines was also demonstrated, supporting earlier intervention with CAR T-cell therapy. Ongoing translational efforts, including single-cell omics analysis, aim to uncover additional factors that affect outcomes to develop more potent treatments.
- 7 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (18) , 3834-3843
Open AccessFacts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
The genetic reprogramming of T cells with chimeric antigen receptors (CAR) specifically targeting CD19 in B-cell malignancies or B-cell maturation antigen for plasma cell tumors has achieved remarkable success. CAR T-cell therapy represents a revolutionary strategy in personalized cancer care, leveraging the immune system's precision to target cancer cells with unprecedented efficacy. However, challenges persist, with resistance and relapse occurring in hematologic malignancies. Understanding the intricate mechanisms governing response and resistance is crucial, emphasizing factors such as pharmacokinetics, product attributes, and tumor biology. This review focuses on biomarkers associated with CAR T-cell therapy in mature B-cell non-Hodgkin lymphoma malignancies, underscoring the importance of preexisting tumor immune contexture. Previous findings highlight strong correlation between early peak levels of CAR-T cells after treatment initiation and treatment response. Maintaining an optimal CAR T-cell–to–tumor burden ratio is essential for sustained responses. Systemic and tumor immune contexture affects therapy outcomes, revealing preexisting immunity's role in CAR T-cell efficacy. The mechanistic impact of CAR-T cells was investigated using pre- and posttreatment biopsies, revealing specific markers associated with treatment response in refractory large B-cell lymphoma, across patients receiving CAR T-cell therapy in the second- and third-line settings, supporting precision medicine in developing next-generation cell therapies for hematologic malignancies. The evolution of the tumor microenvironment with therapy lines was also demonstrated, supporting earlier intervention with CAR T-cell therapy. Ongoing translational efforts, including single-cell omics analysis, aim to uncover additional factors that affect outcomes to develop more potent treatments.
- Open Access
- 12 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
IL-4 drives exhaustion of CD8+ CART cells
Durable response to chimeric antigen receptor T (CART) cell therapy remains limited in part due to CART cell exhaustion. Here, we investigate the regulation of CART cell exhaustion with three independent approaches including: a genome-wide CRISPR knockout screen using an in vitro model for exhaustion, RNA and ATAC sequencing on baseline and exhausted CART cells, and RNA and ATAC sequencing on pre-infusion CART cell products from responders and non-responders in the ZUMA-1 clinical trial. Each of these approaches identify interleukin (IL)-4 as a regulator of CART cell dysfunction. Further, IL-4-treated CD8+ CART cells develop signs of exhaustion independently of the presence of CD4+ CART cells. Conversely, IL-4 pathway editing or the combination of CART cells with an IL-4 monoclonal antibody improves antitumor efficacy and reduces signs of CART cell exhaustion in mantle cell lymphoma xenograft mouse models. Therefore, we identify both a role for IL-4 in inducing CART exhaustion and translatable approaches to improve CART cell therapy.
- 12 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessIL-4 drives exhaustion of CD8+ CART cells
Durable response to chimeric antigen receptor T (CART) cell therapy remains limited in part due to CART cell exhaustion. Here, we investigate the regulation of CART cell exhaustion with three independent approaches including: a genome-wide CRISPR knockout screen using an in vitro model for exhaustion, RNA and ATAC sequencing on baseline and exhausted CART cells, and RNA and ATAC sequencing on pre-infusion CART cell products from responders and non-responders in the ZUMA-1 clinical trial. Each of these approaches identify interleukin (IL)-4 as a regulator of CART cell dysfunction. Further, IL-4-treated CD8+ CART cells develop signs of exhaustion independently of the presence of CD4+ CART cells. Conversely, IL-4 pathway editing or the combination of CART cells with an IL-4 monoclonal antibody improves antitumor efficacy and reduces signs of CART cell exhaustion in mantle cell lymphoma xenograft mouse models. Therefore, we identify both a role for IL-4 in inducing CART exhaustion and translatable approaches to improve CART cell therapy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
T cell–based therapies have induced cancer remissions, though most tumors ultimately progress, reflecting inherent or acquired resistance including antigen escape. Better understanding of how T cells eliminate tumors will help decipher resistance mechanisms. We used a CRISPR/Cas9 screen and identified a necessary role for Fas–FasL in antigen-specific T-cell killing. We also found that Fas–FasL mediated off-target “bystander” killing of antigen-negative tumor cells. This localized bystander cytotoxicity enhanced clearance of antigen-heterogeneous tumors in vivo, a finding that has not been shown previously. Fas-mediated on-target and bystander killing was reproduced in chimeric antigen receptor (CAR-T) and bispecific antibody T-cell models and was augmented by inhibiting regulators of Fas signaling. Tumoral FAS expression alone predicted survival of CAR-T–treated patients in a large clinical trial (NCT02348216). These data suggest strategies to prevent immune escape by targeting both the antigen expression of most tumor cells and the geography of antigen-loss variants.Significance:This study demonstrates the first report of in vivo Fas-dependent bystander killing of antigen-negative tumors by T cells, a phenomenon that may be contributing to the high response rates of antigen-directed immunotherapies despite tumoral heterogeneity. Small molecules that target the Fas pathway may potentiate this mechanism to prevent cancer relapse.This article is highlighted in the In This Issue feature, p. 521
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
T cell–based therapies have induced cancer remissions, though most tumors ultimately progress, reflecting inherent or acquired resistance including antigen escape. Better understanding of how T cells eliminate tumors will help decipher resistance mechanisms. We used a CRISPR/Cas9 screen and identified a necessary role for Fas–FasL in antigen-specific T-cell killing. We also found that Fas–FasL mediated off-target “bystander” killing of antigen-negative tumor cells. This localized bystander cytotoxicity enhanced clearance of antigen-heterogeneous tumors in vivo, a finding that has not been shown previously. Fas-mediated on-target and bystander killing was reproduced in chimeric antigen receptor (CAR-T) and bispecific antibody T-cell models and was augmented by inhibiting regulators of Fas signaling. Tumoral FAS expression alone predicted survival of CAR-T–treated patients in a large clinical trial (NCT02348216). These data suggest strategies to prevent immune escape by targeting both the antigen expression of most tumor cells and the geography of antigen-loss variants.Significance:This study demonstrates the first report of in vivo Fas-dependent bystander killing of antigen-negative tumors by T cells, a phenomenon that may be contributing to the high response rates of antigen-directed immunotherapies despite tumoral heterogeneity. Small molecules that target the Fas pathway may potentiate this mechanism to prevent cancer relapse.This article is highlighted in the In This Issue feature, p. 521